Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/66395
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Pan, Q. | por |
dc.contributor.author | Tian, J. | por |
dc.contributor.author | Zhu, H. | por |
dc.contributor.author | Mao, Z. | por |
dc.contributor.author | Oliveira, Joaquim M. | por |
dc.contributor.author | Reis, R. L. | por |
dc.contributor.author | Xiao, L. | por |
dc.date.accessioned | 2020-08-07T16:29:25Z | - |
dc.date.issued | 2020-03 | - |
dc.date.submitted | 2020-03 | - |
dc.identifier.citation | Pan Q., Tian J., Zhu H., Mao Z., Oliveira J. M., Reis R. L., Xiao L. Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer, ACS Biomaterials Science and Engineering, Vol. 6, Issue 4, pp. 2175-2185, doi:10.1021/acsbiomaterials.0c00163, 2020 | por |
dc.identifier.issn | 2373-9878 | por |
dc.identifier.uri | https://hdl.handle.net/1822/66395 | - |
dc.description.abstract | Synergetic treatments that combine chemotherapy with photothermal/photodynamic therapy have been developed as promising new strategies for cancer therapy, especially for drug-resistant cancers. To achieve optimized synergetic outcomes for cancer therapy, it is highly desirable to selectively and simultaneously deliver both chemotherapeutics and near-infrared photosensitizers to the cancer tissues and cells, enhancing local accumulation. Here we report the preparation of poly-ε-caprolactone nanoparticles (PCL NPs) using bovine albumin as a stabilizer; the nanoparticles are loaded with IR780 and paclitaxel (PTX) for combinational phototherapy and chemotherapy. Moreover, in order to enable active targeting toward ovarian cancer, a specific peptide recognizing luteinizing hormone-releasing hormone receptors (LHRH) on ovarian cancer cells was covalently grafted onto the surface of the as-prepared NPs. As a result, LHRH peptide modified PCL (PCL-LHRH) NPs demonstrated increased internalization in ovarian tumor cells in vitro and selective targeting in tumor xenografts in vivo. PTX and IR780 can be efficiently encapsulated into PCL-LHRH NPs by an oil-in-water emulsion and solvent evaporation method. The systematic administration of ovarian tumor targeting PCL-LHRH/IR780-PTX can efficiently hinder the growth of drug-resistant xenografts in vivo with the assistance of an 808 nm near-infrared laser. These findings indicate that peptide mediated tumor targeting multifunctional nanomaterials may have remarkable profits in controlled drug delivery and synergistic therapy on drug-resistant cancer. | por |
dc.description.sponsorship | The authors are grateful for thefinancial support of theNational Key Research and Development Program of China (2016YFE0132700), the National Natural Science Foundationof China (51673171, 51822306), and the FundamentalResearch Funds for the Central Universities of China(2019XZZX004-07). This study is supported in part by KeyLaboratory of Reproductive Genetics (Zhejiang University),Ministry of Education, P.R. China/Women’s ReproductiveHealth Key Laboratory of Zhejiang Province/Center forUterine Cancer Diagnosis & Therapy Research of ZhejiangProvince (ZDFY2017-RG/RH-001). | por |
dc.language.iso | eng | por |
dc.publisher | ACS Publications | por |
dc.rights | restrictedAccess | por |
dc.subject | Cancer therapy | por |
dc.subject | PCL nanoparticles | por |
dc.subject | Tumor | por |
dc.subject | LHRH peptide | por |
dc.subject | combinational cancer therapy | por |
dc.subject | tumor targeting | por |
dc.subject | drug-resistant ovarian cancer | por |
dc.title | Tumor-targeting polycaprolactone nanoparticles with codelivery of paclitaxel and IR780 for combinational therapy of drug-resistant ovarian cancer | por |
dc.type | article | - |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://pubs.acs.org/doi/abs/10.1021/acsbiomaterials.0c00163 | por |
dc.comments | http://3bs.uminho.pt/node/20274 | por |
oaire.citationStartPage | 2175 | por |
oaire.citationEndPage | 2185 | por |
oaire.citationIssue | 4 | por |
oaire.citationVolume | 6 | por |
dc.date.updated | 2020-08-06T11:27:22Z | - |
dc.identifier.doi | 10.1021/acsbiomaterials.0c00163 | por |
dc.date.embargo | 10000-01-01 | - |
dc.identifier.pmid | 33455308 | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | ACS Biomaterials Science and Engineering | por |
Aparece nas coleções: | 3B’s - Artigos em revistas/Papers in scientific journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
20274-20 ACSBSE Li Xiao.pdf Acesso restrito! | 924,76 kB | Adobe PDF | Ver/Abrir |